{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:31:58Z","timestamp":1792481518316,"version":"4.5.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>There is a need for effective and safe therapies for psoriasis that provide sustained benefits. The aim of this study was to assess the efficacy and safety of tildrakizumab, an anti-interleukin-23p19 monoclonal antibody, for treating moderate-to-severe plaque psoriasis in Chinese patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this multi-center, double-blind, phase III trial, patients with moderate-to-severe plaque psoriasis were enrolled and randomly assigned (1:1) to receive subcutaneous tildrakizumab 100 mg or placebo at weeks 0 and 4. Patients initially assigned to placebo were switched to receive tildrakizumab at weeks 12, 16, and every 12 weeks thereafter. Patients in the tildrakizumab group continued with tildrakizumab at week 16, and every 12 weeks until week 52. The primary endpoint was the Psoriasis Area and Severity Index (PASI 75) response rate at week 12.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      At week 12, tildrakizumab demonstrated significantly higher PASI 75 response rates (66.4% [73\/110]\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      12.7% [14\/110]; difference, 51.4% [95% confidence interval (CI), 40.72, 62.13];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001) and Physician's Global Assessment (60.9% [67\/110]\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      10.0% [11\/110]; difference, 49.1% [95% CI, 38.64, 59.62];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001) compared to placebo. PASI 75 response continued to improve over time in both tildrakizumab and placebo-switching to tildrakizumab groups, reaching maximal efficacy after 28 weeks (86.8% [92\/106]\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . 82.4% [89\/108]) and maintained up to 52 weeks (91.3% [95\/104]\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . 87.4% [90\/103]). Most treatment-emergent adverse events were mild and not related to tildrakizumab.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Tildrakizumab demonstrated durable efficacy through week 52 and was well tolerated in Chinese patients with moderate-to-severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT05108766.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000002873","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T04:00:21Z","timestamp":1704772821000},"page":"1190-1198","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension"],"prefix":"10.1097","volume":"137","author":[{"given":"Chen","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songmei","family":"Geng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Dermatology Hospital of Southern Medical University, Guangzhou, Guangdong 510091, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhua","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuqiu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Second Hospital of Jilin University, Changchun, Jilin 130041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang 830001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingye","family":"Bi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wuxi People's Hospital of Wuxi City, Wuxi, Jiangsu 214023, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong 250022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Beijing Tsinghua Changgung Hospital, Beijing 102218, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 310014, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongwei","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Xinxiang Medical College, Xinxiang, Henan 453100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinsuo","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Affiliated Hospital of Chengde Medical University, Chengde, Hebei 067000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiquan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yuebei People's Hospital, Shaoguan, Guangdong 512026, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Union Hospital Tongji Medical Collage Huazhong University of Science and Technology, Wuhan, Hubei 430022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereal Diseases, The First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Yin","sequence":"additional","affiliation":[{"name":"Shenzhen Kangzhe Biotechnology Co., Ltd., Shenzhen, Guangdong 518052, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"key":"R1-20250602","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"R2-20250602","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: A meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"key":"R3-20250602","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R4-20250602","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3390\/jcm11061506","article-title":"Adherence and persistence to biological drugs for psoriasis: Systematic review with meta-analysis","volume":"11","author":"Piragine","year":"2022","journal-title":"J Clin Med"},{"key":"R5-20250602","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): Results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"R6-20250602","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/bjd.19866","article-title":"Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: Pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)","volume":"185","author":"Thaci","year":"2021","journal-title":"Br J Dermatol"},{"key":"R7-20250602","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/1346-8138.15789","article-title":"Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1)","volume":"48","author":"Igarashi","year":"2021","journal-title":"J Dermatol"},{"key":"R8-20250602","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/1346-8138.15763","article-title":"Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1)","volume":"48","author":"Imafuku","year":"2021","journal-title":"J Dermatol"},{"key":"R9-20250602","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: Development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R10-20250602","first-page":"134","article-title":"Longitudinal data analysis of continuous and discrete responses for pre-post designs","volume":"62","author":"Liang","year":"2000","journal-title":"Sankhy\u0101: Indian J Stat Ser B (1960-2002)"},{"key":"R11-20250602","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): Results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"R12-20250602","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/bjd.21743","article-title":"Efficacy and safety of mirikizumab in psoriasis: Results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)","volume":"187","author":"Blauvelt","year":"2022","journal-title":"Br J Dermatol"},{"key":"R13-20250602","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): Results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"R14-20250602","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): Results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br J Dermatol"},{"key":"R15-20250602","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/jdv.16187","article-title":"Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis","volume":"34","author":"Poulin","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R16-20250602","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/annrheumdis-2020-219014","article-title":"Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: Results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R17-20250602","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/bjd.13932","article-title":"Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"R18-20250602","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/bjd.16724","article-title":"Safety of tildrakizumab for moderate-to-severe plaque psoriasis: Pooled analysis of three randomized controlled trials","volume":"179","author":"Blauvelt","year":"2018","journal-title":"Br J Dermatol"},{"key":"R19-20250602","doi-asserted-by":"crossref","first-page":"17562864221079682","DOI":"10.1177\/17562864221079682","article-title":"Clinically reversible ustekinumab-induced encephalopathy: Case report and review of the literature","volume":"15","author":"Sarto","year":"2022","journal-title":"Ther Adv Neurol Disord"},{"key":"R20-20250602","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"R21-20250602","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1097\/CM9.0000000000002143","article-title":"Effects of adalimumab and secukinumab on comorbidities associated with metabolism in patients with plaque psoriasis","volume":"135","author":"Zhang","year":"2022","journal-title":"Chin Med J"},{"key":"R22-20250602","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"R23-20250602","first-page":"360","article-title":"Efficacy and safety of ixekizumab in Chinese patients with plaque psoriasis","volume":"136","author":"Huang","year":"2023","journal-title":"Chin Med J"},{"key":"R24-20250602","doi-asserted-by":"crossref","first-page":"adv00683","DOI":"10.2340\/actadv.v102.1993","article-title":"Safety of brodalumab in plaque psoriasis: Integrated pooled data from five clinical trials","volume":"102","author":"Reich","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"R25-20250602","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaad.2021.02.057","article-title":"Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data","volume":"85","author":"Shear","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"R26-20250602","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40257-019-00435-9","article-title":"Tildrakizumab: A review in moderate-to-severe plaque psoriasis","volume":"20","author":"Frampton","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"R27-20250602","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/jdv.16964","article-title":"Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: Post hoc analysis through 64 weeks from reSURFACE 1 trial","volume":"35","author":"Warren","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002873","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T15:03:53Z","timestamp":1748876633000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000002873","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,9]]},"assertion":[{"value":"2023-06-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}